Korglutide

Korglutide is an orally administered GLP-1 peptide developed by Caregen as a next-generation solution for weight loss and metabolic improvement. Unlike injectable GLP-1 receptor agonists (e.g., semaglutide, liraglutide), Korglutide is designed as a nutraceutical that offers once-daily oral administration, providing superior patient convenience, compliance, and regulatory accessibility. Korglutide enables fat loss without muscle loss, while also demonstrating clinically meaningful improvements in glycemic control in individuals with type 2 diabetes. It targets both obese and non-obese individuals seeking safe, sustained metabolic benefits.